Ameyer.me

In their recent perspective, Chen et al. observe that the leap from single-cell phenotypes to whole-organ function is too vast to be bridged by purely data-driven methods.

A close friend inspired me to turn my recent blog post into a response to a recent RFI from the National Cancer Institute.

There’s a great deal of talk these days about building “foundation models” of cells and employing large-scale AI in biology.

While uncertain, all signs point to a prolonged period of significantly reduced funding for science.

A delightful new ecosystem of open source productivity tools has taken shape over the last few years.

It has been four years since I last posted.

Antibodies are central to the treatment of cancer—we use them to block certain cell surface receptor signaling, to label cancer cells for destruction by the immune system, and to block signals that are preventing immune responses.

Last year in our machine learning/data analysis class, we had a bit of extra time to take a step back and return why we were there in the first place.

I have to admit I didn’t know Linus Pauling’s second Nobel was for the Peace Prize.

This past year came with a significant increase in the number and complexity of funding proposals I put together.